‘Results of a major UK trial of pre-exposure prophylaxis (PrEP) have been described as “extremely exciting” and a “game-changer” by leading specialists.’
‘An estimated 2,800 gay men acquired HIV in the UK in 2013 and the rate of new infections has remained high for a decade. Six per cent of gay and bisexual men are now living with HIV, rising to 13 per cent in London.’
‘The Proud study [funded by government agencies, the Medical Research Council and Public Health England] found that PrEP cut the risk of HIV infection among gay men considered to be at high risk by an unprecedented 86 per cent. The Proud trial, which took place across 12 NHS trusts in Brighton, London, York, Manchester, Birmingham and Sheffield, was set up to provide real-world evidence on the pill’s effectiveness, and to answer outstanding questions, such as whether providing it would lead to reduced use of condoms. Among the 276 men given PrEP immediately, there were only three HIV infections in the first year of the study, compared with 19 among the deferred group.’
‘The pill used in the trial, Truvada, is a combination of two antiretroviral drugs which has previously been used to treat HIV infection. Developed by Gilead, its newly established ability to prevent as well as treat the virus marks a major turning point in efforts to combat HIV among high-risk groups.’
‘With evidence of its effectiveness now established, it will have to consider whether the pills, which will cost £423 per month for each patient, will be cost-effective, and what the criteria should be for accessing them.’
PrEP has been available to at-risk groups in the United States since 2012.’
See:
HIV pill: Scientists hail discovery of ‘game-changer’ that cuts the risk of infection among gay men by 86%